The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs
The DOI matches its Crossref record.
Abstract
BACKGROUND: Approximately 50% of patients diagnosed with major depressive disorder will experience a recurrent or chronic course of illness for which long-term treatment is recommended. Moreover, at least 20% of patients diagnosed with depression do not respond satisfactorily to several traditional antidepressant medication treatment trials. Very little is known about the health care costs of patients with treatment-resistant depression. METHOD: Based on medical claims data (MarketScan Research Database, The MEDSTAT Group, Cambridge, Mass.) from January 1, 1995, to June 30, 2000, a naturalistic, retrospective analysis was conducted to study the characteristics and health care utilization of patients with treatment-resistant depression. All patients having an International Classification of Diseases, Ninth Revision (ICD-9), diagnosis code for unipolar or bipolar depression with specified antidepressant dosing and treatment durations were initially selected. Patients were then classified as "treatment resistant" if either they switched from or augmented initial antidepressant medication with other antidepressants at least twice (outpatient treatment-resistant group) or they switched from or augmented their initial antidepressant medication and also had a claim for either a depression-related hospitalization or suicide attempt (hospitalized treatment-resistant group). Those meeting the initial medication and diagnosis selection criteria but not meeting the treatment-resistance criteria constituted the comparison group. Members of the comparison group had comparatively stable antidepressant medication use patterns, consistent with an acceptable response to treatment. Patients were followed for a minimum of 9 months. Resource utilization was calculated from index date to last available claims data point and then annualized. RESULTS: Treatment-resistant patients were more likely to be diagnosed with bipolar disorder or concurrent substance abuse or anxiety disorders than the comparison group (p <.001). Treatment-resistant patients were at least twice as likely to be hospitalized (general medical and depression related) and had at least 12% more outpatient visits (p <.02). Treatment resistance was also associated with use of 1.4 to 3 times more psychotropic medications (including antidepressants) (p <.001). Patients in the hospitalized treatment-resistant group had over 6 times the mean total medical costs of non-treatment-resistant depressed patients ($42,344 vs. $6512) (p <.001) and their total depression-related costs were 19 times greater than those of patients in the comparison group ($28,001 vs. $1455) (p <.001). CONCLUSION: Treatment-resistant depression is costly and associated with extensive use of depression-related and general medical services. These findings underscore the need for early identification and effective long-term maintenance treatment for treatment-resistant depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, for approximately 50% of those who suffer from depression, their illness will follow a chronic, relapsing course associated with considerable disability and impairment (Crown 2002).”
From Interventions for preventing relapse and recurrence of a depressive disorder in children and adolescents (2012) · cites this paper as Crown 2002
In the citing paper
“Direct medical costs associated with TRD are estimated to be 2-6 times higher compared with other patients with MDD, 42, 43 with costs increasing with chronicity and severity of TRD. 44”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [43]
In the citing paper
“Patients with TRD are twice as likely to be hospitalised compared with non-TRD patients, and require increased numbers of psychiatric outpatient visits. 43”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [43]
Citations
Cited by
Items 201–300 of 382
The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine
Wilkowska, A., & Cubała, W. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314605 · Cited by 22
Antidepressant Adherence After Psychiatric Hospitalization Among VA Patients with Depression
Zivin, K., Ganoczy, D. A., Pfeiffer, P. N., Miller, E. M., & Valenstein, M. M. (2009) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1007/s10488-009-0230-2 · Cited by 23
“Patients with comorbid depression and substance use may also be more likely to have treatment-resistant depression, which involves more antidepressant switches (Crown et al. 2002).”
Psychosocial treatment approaches to difficult-to-treat depression
Casey, M. F., Perera, D. N., & Clarke, D. M. (2012) · The Medical Journal of Australia · doi:10.5694/mja12.10629 · Cited by 21
Brand, S. J., & Harvey, B. H. (2016) · Acta Neuropsychiatrica · doi:10.1017/neu.2016.50 · Cited by 21
“The impact of TRD on healthcare expenditure is proportional to the degree of resistance (10), requiring more frequent hospitalisation (11), increased use of pharmacotherapy (11) together with an increased disease burden (8).”
BackgroundDeep brain stimulation for treatment-resistant depression: a safe and effective option
Torre, D. L., Torre, A. D., Chirchiglia, D., Volpentesta, G., Guzzi, G., & Lavano, A. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1749049 · Cited by 20
“In all examined studies, it is observed the use of a varied range of amplitudes of stimulation; in some particular cases (use of high amplitudes), the need for a considerable amount of electrical current delivered raises the problem of battery exhaustion and the opportunity to use rechargeable devices [47,48].”
BackgroundTreatment Resistance and Psychodynamic Psychiatry: Concepts Psychiatry Needs from Psychoanalysis
Plakun, E. M. (2012) · Psychodynamic Psychiatry · doi:10.1521/pdps.2012.40.2.183 · Cited by 25
“We have also learned that the overall medical costs associated with treatment resistant depression are 19 times higher than those for patients with treatment responsive depression (Crown et al., 2002).”
BackgroundTowards translational modeling of behavioral despair and its treatment in zebrafish
Kositsyn, Y. M., Volgin, A. D., de Abreu, M. S., Demin, K. A., Zabegalov, K. N., Maslov, G. O., Petersen, E. V., Kolesnikova, T. O., Strekalova, T., & Kalueff, A. V. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113906 · Cited by 20
VNS and depression: current status and future directions
Walsh, S. P., & Kling, M. A. (2004) · Expert Review of Medical Devices · doi:10.1586/17434440.1.1.155 · Cited by 19
The bipolar diathesis of treatment-resistant major depressive disorder
Woo, Y. S., Chae, J., Jun, T., Kim, K., & Bahk, W. (2008) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500701749867 · Cited by 20
“Treatment-related risk factors include an inadequate dose and duration of antidepressant treatment, inaccurate diagnosis or misdiagnosis and treatment noncompliance [4,5].”
BackgroundResultTreatment-Refractory Mood Disorders: A Psychodynamic Perspective
Plakun, E. M. (2003) · Journal of Psychiatric Practice · doi:10.1097/00131746-200305000-00004 · Cited by 22
Castelpietra, G., Gobbato, M., Valent, F., Vido, C. D., Balestrieri, M., & Isacsson, G. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2236-0 · Cited by 18
“Although the indication for switching or combining antidepressants regards the patients with treatment-resistant depression [31], previous studies have suggested that patients who receive more prescriptions [32], as well as frequently change treatment [11, 15, 33], may be more resistant to antidepressants.”
BackgroundBirnbaum, H. G., Ben-Hamadi, R., Kelley, D., Hsieh, M., Seal, B. S., Kantor, E., Crémieux, P., & Greenberg, P. E. (2010) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0b013e3181cb5b10 · Cited by 22
Rational antidepressant selection: applying evidence-based medicine to complex real-world patients.
Zetin, M., Hoepner, C. T., & Bjornson, L. (2006) · PubMed · Cited by 17
Depressive symptoms in elderly participants of an open university for elderly
Batistoni, S. S. T., Ordonez, T. N., da Silva, T. B. L., do Nascimento, P. P. P., Kissaki, P. T., & Cachioni, M. (2011) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642011dn05020005 · Cited by 16
“The symptoms of depression, although more unstable in later life than during other times, may become a chronic or recurrent condition in around 50% of older adults affected, especially among ailing elderly.(5) Due to the reduced chance of aging well, increased family burden and higher healthcare utilization associated…”
BackgroundDurden, E., Alemayehu, B., Bouchard, J. R., Chu, B. C., & Aagren, M. (2009) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0b013e3181c2bb31 · Cited by 16
Adverse Effects of Second-Generation Antipsychotics as Adjuncts to Antidepressants
Thase, M. E. (2016) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2016.04.008 · Cited by 15
Current perspectives in the management of treatment-resistant depression
Parikh, R. M., & Lebowitz, B. D. (2004) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2004.6.1/rparikh · Cited by 18
“Patients in the hospitalized TRD group had over 6 times the mean total medical costs of non-TRD patients (US$ 42 344 versus US$ 6512) and their total depressionrelated costs were 19 times greater than those of patients in the comparison group (US$ 28 001 versus US$ 1455).(15) These findings emphasize the need for earl…”
Vagus Nerve Stimulation for Severe Depression
Rado, J. T., & Janicak, P. G. (2007) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20070701-10 · Cited by 17
Treatment‐resistant Depression
Möller, H., Seemüller, F., Schennach, R., & Gupta, R. K. (2013) · Wiley eBooks · doi:10.1002/9781118556719.ch2 · Cited by 15
Allen, N. B., Hetrick, S. E., Yap, M. B. H., & Simmons, J. G. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007504 · Cited by 15
Zhdanava, M., Kuvadia, H., Joshi, K., Daly, E., Pilon, D., Rossi, C., Morrison, L., Lefèbvre, P., & Nelson, C. J. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1844645 · Cited by 15
Sharma, V. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.04.058 · Cited by 14
Chen, T., & Tzeng, N. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.05.009 · Cited by 15
“Most antidepressants take as long as 4–6 weeks to produce a therapeutic response [4], and only 25–35% of all patients achieve remission with antidepressant monotherapy [5].”
BackgroundHassan, A. K., Farmer, K. C., Brahm, N. C., & Neas, B. R. (2016) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-016-0272-y · Cited by 15
Fu, A. Z., Christensen, D. B., Hansen, R. A., & Liu, G. G. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.06.011 · Cited by 12
Ball, S. G., Classi, P. M., & Dennehy, E. B. (2014) · Annals of General Psychiatry · doi:10.1186/1744-859x-13-8 · Cited by 13
“Both US and international studies have demonstrated that patients who have a partial or non-response, and who require additional treatment, are more costly compared with patients who achieve remission with an initial treatment intervention [23,24].”
BackgroundCohen, L. J., & Allen, J. C. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802229050 · Cited by 13
Therapeutic Armamentarium for Treating Depression
Howland, R. H. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.07.2176 · Cited by 15
Fang, C., Hayashi, S., Du, X., Cai, X., Deng, B., Zheng, H., Ishido, S., Tsutsui, H., & Sheng, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-86659-4 · Cited by 12
Kabotyanski, K. E., Najera, R. A., Banks, G. P., Sharma, H., Provenza, N. R., Hayden, B. Y., Mathew, S. J., & Sheth, S. A. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02951-7 · Cited by 13
“All cost data, including costs associated with complications, were collected from the 2023 Centers for Medicare & Medicaid Services (CMS) Physician Fee Schedule (based on HCPCS/CPT codes) [47] and from published health economics literature [48 – 60].”
MethodPsychotherapy and Psychosocial Treatment
Plakun, E. M. (2015) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2015.05.012 · Cited by 18
“We are also learning about the costs of treatment resistance, with overall medical costs 19 times higher for treatment resistant depression than for more treatment responsive depression.(40) These costs do not take into account lost”
BackgroundLloret‐Linares, C., Bellivier, F., Haffen, É., Aubry, J., Daali, Y., Heron, K., Berney, P., Desmeules, J. A., & Besson, M. J. (2015) · Current Drug Metabolism · doi:10.2174/138920021601150702160728 · Cited by 12
Predicting Incident Treatment-Resistant Depression: A Model Designed for Health Systems of Care
Liberman, J. N., Davis, T., Pesa, J., Chow, W., Verbanac, J., Heverly-Fitt, S., & Ruetsch, C. R. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.8.987 · Cited by 12
Teobaldi, E., Pessina, E., Martini, A., Cattaneo, C. I., Berardis, D. D., Martiadis, V., Maina, G., & Rosso, G. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666240129095852 · Cited by 14
“Treatment-resistant depression is one of the leading problems in psychiatry with serious consequences in terms of patient's functioning and quality of life as well as resource utilization in both Major Depressive Disorder and BD [16, 23-25].”
BackgroundAssessing potential of psilocybin for depressive disorders
Kozak, Z., Johnson, M. W., & Aaronson, S. T. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2273493 · Cited by 11
Conway, C. R., Rush, A. J., Aaronson, S. T., Bunker, M. T., Gordon, C., George, M. S., Riva‐Posse, P., Allen, R. M., Nahas, Z. H., Kriedt, C. L., et al. (2026) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf080 · Cited by 13
Self-citationThe Role of Psychotherapy in the Management of Treatment-Resistant Depression
Rogan, T., & Wilkinson, S. T. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.006 · Cited by 16
Gerson, L. B., Bonafede, M., Princic, N., Gregory, C., Farr, A., & Balu, S. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04755.x · Cited by 11
Jing, Y., Kalsekar, I. D., Curkendall, S. M., Carls, G. S., Bagalman, E., Forbes, R. A., Hebden, T., & Thase, M. E. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.07.015 · Cited by 11
Clinical Utility and Economic Impact of CYP2D6 Genotyping
Reynolds, K. K., McNally, B. A., & Linder, M. W. (2016) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2016.05.008 · Cited by 12
“Studies have shown that 30% to 46% of depressed patients do not adequately respond to their initial antidepressant and that discontinuation of the first-line antidepressant therapy is a major determinant for which patients are likely to become treatment resistant.(54) Russell and colleagues(56) (Table 4) demonstrated…”
BackgroundResultInfluentialFrom TADS and SOFTADS to TORDIA and Beyond: What’s New in the Treatment of Adolescent Depression?
Yu, Z. J., Kratochvil, C. J., Weller, R. A., Mooreville, M., & Weller, E. B. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0094-x · Cited by 16
“TRD also has a significant economic impact due to lost productivity and treatment of associated medical conditions [30].”
BackgroundNadkarni, A., Kalsekar, You, Hebden, & Forbes (2013) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s36526 · Cited by 11
“Not only does this inadequate response to ADT present a clinical complication, it also has economic implications.(8,9) Studies have shown that patients who respond inadequately to ADT experience a disproportionate burden of illness,(4,9,10) particularly as the disease increases in severity.”
Síntomas depresivos en adultos mayores participantes de una universidad abierta a la tercera edad
Ordonez, T. N., Batistoni, S. S. T., & Cachioni, M. (2011) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2010.11.010 · Cited by 11
Boer, S., Dekkers, O. M., le Cessie, S., Carlier, I. V. E., & van Hemert, A. M. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.12.035 · Cited by 13
The economic burden associated with SSRI treatment failure in a managed care population
Balkrishnan, R., Joish, V. N., Yang, T. T., Jayawant, S. S., & Mullins, C. D. (2008) · Journal of Medical Economics · doi:10.3111/13696990802522339 · Cited by 13
(2013) · PubMed
Halpern, R., Nadkarni, A., Kalsekar, I. D., Nguyen, H. P., Song, R., Baker, R. A., & Nelson, J. C. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r622 · Cited by 11
Association of clinical features and biomarkers with treatment-resistant depression
Congio, A. C., Norcia, M., Urbano, M. R., Verri, W. A., Jr., & Nunes, S. O. V. (2020) · Neurology Psychiatry and Brain Research · doi:10.1016/j.npbr.2020.02.004 · Cited by 12
Shim, S.-H., Woo, Y. S., Kim, J. S., Heo, I. S., Yoon, H. J., Sung, H. M., Lee, J., & Bahk, W. (2022) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2022.20.1.143 · Cited by 10
Use of Cortical Stimulation in Neuropathic Pain, Tinnitus, Depression, and Movement Disorders
Panov, F. E., & Kopell, B. H. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0283-0 · Cited by 10
Aktueller Stand und Perspektiven der Forschung
Rush, A. J. (2005) · Springer eBooks · doi:10.1007/3-540-28049-9_1 · Cited by 12
Self-citationSun, J., Xu, L., Ma, Y., Guo, C., Du, Z., Gao, S., Luo, Y., Chen, Q., Yang, H., Yu, X., et al. (2022) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2022.111567 · Cited by 10
“The cost of care for patients with TRD is more than six times the average total cost for patients with nTRD, and the rate of outpatient and emergency room visits is higher (Crown et al., 2002; McIntyre et al., 2020).”
BackgroundRen, X.-Y., Rubini, P., Engel, T., Tang, Y., & Illés, P. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107989 · Cited by 11
Arnaud, A. M., Benner, J., Suthoff, E. D., WERNEBURG, B. G., Reinhart, M. L., Sussman, M., & Kessler, R. C. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.12.147 · Cited by 11
Owashi, T., Otsubo, T., Oshima, A., Nakagome, K., Higuchi, T., & Kamijima, K. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.01.006 · Cited by 9
Leposavić, L., Dimitrijević, D., Đorđević, S., Leposavić, I., & Balkoski, G. N. (2015) · PubMed · Cited by 9
The Place for Psychodynamic Therapy and Obstacles to Its Provision
Lazar, S. G. (2018) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2018.01.004 · Cited by 9
Using the Addiction Severity Index to Predict Mental and Medical Health Service Utilization
Wryobeck, J. M., Chermack, S. T., Closser, M. H., & Blow, F. C. (2006) · Journal of Addictive Diseases · doi:10.1300/j069v25n04_01 · Cited by 9
Ji, M., Feng, J., & Liu, G. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299020 · Cited by 13
“Significantly higher hospitalization rates and medical costs have been observed in patients with TRD and MDD patients compared with other patients [9].”
ResultRetractedExploring cariprazine as a treatment option for varied depression symptom clusters
Pejušković, B., Munjiza, A., & Pešić, D. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1442699 · Cited by 11
Health care utilisation in treatment-resistant depression: a Swedish population-based cohort study
Brenner, P., Nygren, A., Hägg, D., Tiger, M., O’Hara, M., Brandt, L., & Reutfors, J. (2021) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2021.2003405 · Cited by 9
“claims data have reported increased HCU in TRD patients both compared to non-TRD patients and to healthy controls (Crown et al. 2002; Pilon et al., 2019; Shrestha et al. 2020; Benson et al. 2020; Li et al. 2020).”
BackgroundResultLaboratory medicine: The exemplar for value-based healthcare
Arshoff, L., Hoag, G. N., Ivany, C., & Kinniburgh, D. W. (2021) · Healthcare Management Forum · doi:10.1177/0840470421990041 · Cited by 8
“Table 2 summarizes four LM examples that illustrate VBHC using the innovative technologies of PM, DP, and POCT.”
InfluentialBest, S. R. D. (2015) · Neuropsychiatric Electrophysiology · doi:10.1186/s40810-015-0003-y · Cited by 8
“Background Treatment resistant depression (TRD) is a major public health issue, with at least 20% of patients failing to respond to more than one traditional antidepressant (Crown et al. 2002; Sackeim 2001).”
BackgroundAntidepressant chronotherapeutics in a group of drug free outpatients
Dallaspezia, S., & van Jaarsveld, A. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.04.104 · Cited by 8
“In everyday clinical practice antidepressant drugs are the mainstay for the treatment of depression, but treatment efficacy is lower than desired (Crown et al., 2002).”
Do we need new therapeutic strategies for depression?
Mihaljević-Peleš, A., Šagud, M., Janović, M. B., Mikulić, S. K., & Jevtović, S. (2011) · PubMed · Cited by 8
Lloret‐Linares, C., Daali, Y., Chevret, S., Nieto, I., Molière, F., Courtet, P., Galtier, F., Richieri, R. M., Morange, S., Llorca, P., et al. (2017) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-017-0173-2 · Cited by 8
“Patients with resistance to treatment are twice as likely to be hospitalized, have more outpatient visits, use more psychotropic medications, and have 19 times the depression-related costs compared to patients with depression that responds to treatment [7].”
Treatment-Resistant Depression
Cusin, C., & Peyda, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-97241-1_1 · Cited by 9
Psychosocial treatment approaches to difficult-to-treat depression
Casey, M. F., Perera, D. N., & Clarke, D. M. (2012) · The Medical Journal of Australia · doi:10.5694/mjao12.10629 · Cited by 8
Sozialpsychologie der Depression
Haubl, R. (2005) · Vandenhoeck & Ruprecht eBooks · doi:10.13109/9783666451645.291 · Cited by 11
Attali, D., Daniel, M., Plaze, M., & Aubry, J. (2025) · International Journal of Hyperthermia · doi:10.1080/02656736.2025.2539986 · Cited by 10
“Pharmacoresistance not only exacerbates the individual burden of illness but also leads to a substantial increase in morbidity and healthcare burden and costs, up to 10 times higher than in nonresistant patients [4,5].”
Mindfulness-Based Cognitive Therapy for Treatment-Resistant Depression
Deen, S. R., Sipe, W. E. B., & Eisendrath, S. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-29866-5_12 · Cited by 12
Definition and Epidemiology of Treatment Resistance in Psychiatry
Smith-Apeldoorn, S. Y., Veraart, J. K. E., & Schoevers, R. A. (2018) · Springer eBooks · doi:10.1007/978-981-10-4358-1_1 · Cited by 11
Wu, B., Cai, Q., Sheehan, J. J., Benson, C. J., Connolly, N., & Alphs, L. D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220763 · Cited by 8
Park, H., Park, C. M., Woo, J., Shin, J., Lee, E., & Kwon, S. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1918922 · Cited by 8
Ketamina, da anestesia ao uso abusivo
da Silva, F. C. C., Dantas, R. T., Citó, M. D. C. D. O., Vasconcelos, S. M. M., Fonteles, M. M. D. F., Viana, G. S. D. B., & de Sousa, F. C. F. (2001) · Revista Neurociências · doi:10.34024/rnc.2010.v18.8486 · Cited by 27
Lyons, M. A., & Delgadillo, J. (2024) · British Journal of Clinical Psychology · doi:10.1111/bjc.12513 · Cited by 10
“It is estimated that approximately 50% of individuals with major depressive disorder (MDD) will experience a chronic or recurrent course, and 20% will experience treatment-resistant depression (TRD; Crown et al., 2002).”
Can, A., Hermens, D. F., & Lagopoulos, J. (2022) · Clinical Case Reports · doi:10.1002/ccr3.6675 · Cited by 6
Tardive dysphoria: antidepressant-induced chronic depression
El‐Mallakh, R. S., Roberts, R. J., Swann, A. C., Rutherford, P. R., & Surja, A. (2011) · Irish Journal of Psychological Medicine · doi:10.1017/s0790966700011976 · Cited by 6
Evaluation, Treatment, and Referral of Treatment-Resistant Depression in Primary Care
Chopra, A., Luccarelli, J., Cohen, J. N., Mischoulon, D., & Stern, T. A. (2023) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.22f03438 · Cited by 6
Lamy, F.-X., Chollet, J., Clay, E., Brignone, M., Rive, B., & Saragoussi, D. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1020362 · Cited by 5
Cao, Z., Zou, K. H., Baker, C. L., Su, J., Paulose‐Ram, R., Durden, E., Shi, N., & Shah, H. (2011) · Journal of Medical Economics · doi:10.3111/13696998.2011.552582 · Cited by 5
Liu, Y., Zhou, X., Qin, B., Giovane, C. D., Zhang, Y., & Xie, P. (2014) · Systematic Reviews · doi:10.1186/2046-4053-3-133 · Cited by 6
“will experience a second depressive episode [1-3].”
Haider, S., Grabovac, I., Rieder, A., & Dorner, T. E. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16234697 · Cited by 9
King, C. D., Yip, A. G., Cao, Y., Rodriguez‐Villa, F., Krause, D. S., Dowd, D., & Ressler, K. J. (2020) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2020.100060 · Cited by 5
Ketamine: A Promising Rapid-Acting Antidepressant
Wilkinson, S. T., Ostroff, R. B., Katz, R. B., & Krystal, J. H. (2017) · Springer eBooks · doi:10.1007/978-981-10-6577-4_16 · Cited by 5
Treatment-resistant depression
Werremeyer, A. B. (2014) · Mental Health Clinician · doi:10.9740/mhc.n207177 · Cited by 7
Polygenic dissection of treatment-resistant depression with proxy phenotypes in the UK Biobank
Wang, L.-H., Shih, M.-Y., Lin, K., Kuo, P., & Feng, Y. A. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.012 · Cited by 7
Giguère, S., Fortier, A., Azrak, J., Giguère, C., Potvin, S., & Dumais, A. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15080338 · Cited by 5
“They also use more healthcare resources and impose a greater societal and economic burden than those with treatment-responsive depression [20,21].”
Engels, A., Reber, K. C., Magaard, J. L., Härter, M. C., Hawighorst‐Knapstein, S., Chaudhuri, A., Brettschneider, C., & König, H. (2020) · The European Journal of Health Economics · doi:10.1007/s10198-020-01170-3 · Cited by 5
The Cost-Effectiveness of Psychodynamic Therapy: The Obstacles, the Law, and a Landmark Lawsuit
Lazar, S. G. (2021) · Psychoanalytic Inquiry · doi:10.1080/07351690.2021.1983404 · Cited by 6
“The treatment resistant depressed group has 12% more outpatient visits, 1.4 to 3 times more psychotropic medications, over 6 times the mean total medical costs, and 19 times greater total depression-related costs (Crown et al., 2002).”
BackgroundInfluentialTeng, C.-T., Caldieraro, M. A., Lacerda, A. L. T., Nardi, A. E., Quarantini, L. C., Souza, F., Corrêa, H., KANEVSKY, G. A., & Cabrera, P. (2021) · Jornal Brasileiro de Economia da Saúde · doi:10.21115/jbes.v13.n3.p310-21 · Cited by 5
Trajectories of pharmacological therapies for treatment-resistant depression: a longitudinal study
DiBello, J. R., Xiong, X., Liu, X., Zhong, W., Merola, A., Li, M., & Lu, K. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06518-8 · Cited by 7
Ershadi, A. S. B., & Hosseini, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817933-8.00036-0 · Cited by 6
Shearer, J., Lynch, T. R., Chamba, R., Clarke, S. E., Hempel, R., Kingdon, D., O’Mahen, H., Remington, B., Rushbrook, S. C., Russell, I. T., et al. (2019) · BJPsych Open · doi:10.1192/bjo.2019.57 · Cited by 5
Antai-Otong, D. (2007) · Perspectives In Psychiatric Care · doi:10.1111/j.1744-6163.2007.00123.x · Cited by 5
Beyond depression symptoms: the default mode network as a predictor of antidepressant response
Zheng, K., Chen, L., Wang, H., Cao, L., Chen, G.-M., Chen, J.-S., Chen, T., Chen, T.-L., Cheng, Y.-Q., Chu, Z., et al. (2026) · npj Mental Health Research · doi:10.1038/s44184-025-00182-2 · Cited by 4
“Spe-ci fi cally, TRD individuals have twice the probability of hospitalization, incurring a cost exceeding six times the mean total cost for non-treatment-resistant depressed patients 39 .”
Tamayo, J. M., Ruiz, Y. P., & Ruíz, I. (2015) · Archivos de Neurociencias · doi:10.31157/an.v20i1.66 · Cited by 3
Kong, F., Ji, C., Du, X., Logan, R. A., Zhao, H.-Y., Wu, G.-H., Liu, Y., Tang, Z., & Niu, M. (2021) · Aging · doi:10.18632/aging.203477 · Cited by 7
Effect of Reliable Recovery on Health Care Costs and Productivity Losses in Emotional Disorders
Barrio‐Martínez, S., Ruiz‐Rodríguez, P., Medrano, L. A., Priede, A., Muñoz‐Navarro, R., Moriana, J. A., Carpallo-González, M., Prieto-Vila, M., Vindel, A. C., & González‐Blanch, C. (2023) · Behavior Therapy · doi:10.1016/j.beth.2023.08.012 · Cited by 3
Non-Response to Initial Antidepressant Therapy
Guilloux, J., David, D. J. P., Samuels, B. A., Mendez‐David, I., Gardier, A. M., & Guiar, B. P. (2012) · InTech eBooks · doi:10.5772/37783 · Cited by 4
“…are 6-times higher than those associated with non treatment-resistant depression ($42,344 vs. $6512) and the total depression-related costs of resistance are 19-times higher than those of patients with nontreatment-resistant MD ($28,001 vs. $1455) (Crown et al., 2002; Ivanova et al., 2010).”
Background
Metadata
- Authors
- Crown, W. H., Finkelstein, S., Berndt, E. R., Ling, D., Poret, A. W., Rush, A. J., & Russell, J. M.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2002-11-15
- Volume
- 63
- Issue
- 11
- Pages
- 963-971
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2098750661
- Cited by
- 386
- References
- 0
- Citations by year
- 2026: 16 · 2025: 13 · 2024: 13 · 2023: 23 · 2022: 20 · 2021: 17 · 2020: 17 · 2019: 18 · 2018: 16 · 2017: 9 · 2016: 15 · 2015: 17 · 2014: 19 · 2013: 19 · 2012: 17
- FWCI
- 6.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- treatment-resistant depression, major depressive disorder, bipolar disorder, health care utilization, health care costs, antidepressants, hospitalization, psychotropic drug use, substance use comorbidity, anxiety disorders, health insurance claims data, suicide attempts, outpatient visits, chronic depression, recurrent depression
- MeSH terms
- Adult, Ambulatory Care, Bipolar Disorder, Costs and Cost Analysis, Depressive Disorder, Major, Major Depressive Disorder, Drug Resistance, Female, Humans, Male, Middle Aged, Patient Acceptance of Health Care, Patient Admission, Psychotropic Drugs, Referral and Consultation, Retrospective Studies, Utilization Review, Comorbidity, Drug Costs, Health Care Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.